tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GANX Stock Latest News

Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
RatingsBuy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
11d ago
GANX
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
PremiumRatings
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
12d ago
GANX
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
PremiumThe Fly
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
12d ago
GANX
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
PremiumRatings
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
18d ago
GANX
Gain Therapeutics holds a conference call
PremiumThe Fly
Gain Therapeutics holds a conference call
19d ago
GANX
Gain Therapeutics price target raised to $10 from $6 at Roth Capital
PremiumThe FlyGain Therapeutics price target raised to $10 from $6 at Roth Capital
1M ago
GANX
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
Premium
Ratings
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
1M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
Premium
Ratings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
1M ago
GANX
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
PremiumCompany Announcements
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
1M ago
8K
GANX
Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint
PremiumThe Fly
Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint
1M ago
GANX
Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data
PremiumRatings
Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data
2M ago
GANX
Gain Therapeutics Announces New Stock Offering Program
PremiumCompany Announcements
Gain Therapeutics Announces New Stock Offering Program
2M ago
8K
GANX
Buy Rating for Gain Therapeutics: Promising Innovations in Disease Treatment
PremiumRatingsBuy Rating for Gain Therapeutics: Promising Innovations in Disease Treatment
2M ago
GANX
Gain Therapeutics presents data on GT-02287
Premium
The Fly
Gain Therapeutics presents data on GT-02287
2M ago
GANX
Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating
Premium
Ratings
Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating
2M ago
GANX
Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Drive Buy Rating
PremiumRatings
Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Drive Buy Rating
2M ago
GANX
Gain Therapeutics Reports Continued Progress Amid Financial Challenges
PremiumCompany Announcements
Gain Therapeutics Reports Continued Progress Amid Financial Challenges
2M ago
GANX
Gain Therapeutics reports Q3 EPS (15c), consensus (15c)
PremiumThe Fly
Gain Therapeutics reports Q3 EPS (15c), consensus (15c)
2M ago
GANX
Gain Therapeutics, Inc. (GANX) Q3 Earnings Cheat Sheet
PremiumPre-Earnings
Gain Therapeutics, Inc. (GANX) Q3 Earnings Cheat Sheet
2M ago
GANX
Gain Therapeutics Advances Parkinson’s Treatment with GT-02287 Study
PremiumCompany AnnouncementsGain Therapeutics Advances Parkinson’s Treatment with GT-02287 Study
3M ago
GANX
Unusually active option classes on open October 22nd
Premium
The Fly
Unusually active option classes on open October 22nd
3M ago
T
BB
Buy Rating for Gain Therapeutics: Promising Potential of GT-02287 in Parkinson’s Treatment
Premium
Ratings
Buy Rating for Gain Therapeutics: Promising Potential of GT-02287 in Parkinson’s Treatment
3M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >